# Jasper Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/jasper-therapeutics

- Industry: Biotechnology
- Headquarters: Redwood City, US
- Website: www.jaspertherapeutics.com
- Total disclosed funding: $49M
- Latest round: Series A (Jan 9, 2020)
- Investors on record: 7

## About

Founded in 2018 by Dr. Judith Shizuru and Dr. Susan Prohaska, and based in California, US, Jasper Therapeutics, Inc. is a biotechnology company that focuses on enabling cures with hematopoietic cells transplants. The company develops hematopoietic transplantations that are possible for all indications for all types of patients including infants, children, the elderly, and other fragile populations.  In 2020, Jasper Therapeutics, Inc. raised USD 14.1 million in Series A funding, as a part of a larger USD 49.1 million Series A funding, led by new investor Roche Venture Fund, with the participation from other new and returning investors. 

In 2021, Jasper Therapeutics, Inc. agreed to merge with Amplitude Healthcare Acquisition Corp., a special purpose acquisition company (SPAC) for USD 100 million. This transaction also includes commitments for a $100 million private investment in public equity (PIPE) priced at $10.00 per share. As of 2021, the company has evaluated JSP191 in over 90 healthy volunteers and patients. 

The company’s pipeline includes its flagship product JSP191, an antibody in clinical development as a conditioning agent to clear stem cells from bone marrow in patients undergoing a hematopoietic cell transplant, creating a space for the donor or gene-corrected transplanted stem cells to engraft. JSP191 is designed to address the limitations of current conditioning by replacing chemotherapy or radiation in patients undergoing curative hematopoietic stem cell transplants and gene therapies. JSP191’s conditioning is used for AML(acute myeloid leukemia)/ MDs (myelodysplastic syndromes), SCID(severe combined immunodeficiency), Fanconi’s Anemia, sickle cell disease, and gene therapy. 

Jasper also provides an engineered hematopoietic stem cell (eHSC) platform to improve the safety and increase the cure rate of allogeneic and autologous gene therapy grafts without the need for toxic conditioning. eHSCs could eliminate the risk of GvHD and the need for long-term immune suppression and have the potential to expand the number of donors available for any given patient. Jasper eHSC Grafts is utilized for Thalassemias, sickle cell diseases, and autoimmune diseases. 

Jasper Therapeutics plans on utilizing the Series A funding to support the clinical development of JSP191. Post the merger with Amplitude Healthcare Acquisition Corp, Jasper Therapeutics Inc., plans on listing on the NASDAQ under the ticker symbol, JSPR. The company plans on utilizing the capital obtained from the merger to accelerate the development of a clinical-stage anti-CD117 antibody transplant conditioning agent and the eHSC platform.

## Funding rounds

- Series A, Jan 9, 2020, $14M — Abingworth, Qiming Venture Partners, Citadel Advisors, Roche Venture Fund, TSVC
- Series A, Dec 6, 2019, $35M — Abingworth, Alexandria Venture Investments, Qiming Venture Partners, Surveyor Capital

## Investors

- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series A
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A
- Surveyor Capital — Series A
- Citadel Advisors — Series A
- Roche Venture Fund (https://capitalatlas.ai/funds/roche-venture-fund) — Series A
- TSVC (https://capitalatlas.ai/funds/tsvc) — Series A